TOKIO–(BUSINESS WIRE)– Solasia Pharma K.K. (TSE: 4597, hoofdkantoor: Tokio, Japan, President & CEO: Yoshihiro Arai, hierna “Solasia”) heeft vandaag officieel aangekondigd dat een organoarseen medicijn “DARVIAS® Injection 135mg” (SP-02, hierna DARVIAS®) is goedgekeurd voor recidiverende of refractair perifeer T-cellymfoom (hierna “PTCL”) door het Ministry of Health, Labor en Welfare (MHLW). Solasia heeft in juni 2021 een NDA ingediend bij de MHLW in Japan. In oktober 2021 heeft Nippon Kayaku Co., Ltd. (TSE: 4272, hoofdkantoor: Tokyo, Japan, president: Atsuhiro Wakumoto) een licentieovereenkomst met DARVIAS® voor marketingrechten afgesloten in Japan.

Solasia Pharma: DARVIAS® Injection 135mg (Generic Name: DARINAPARSIN /Development Code: SP-02) Approved in Japan

TOKYO–(BUSINESS WIRE)– Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS^® Injection 135mg” (SP-02, hereinafter DARVIAS^®) has been approved for relapsed or refractory Peripheral T-Cell Lymphoma (hereinafter “PTCL”) by the Ministry of Health, Labor and Welfare (MHLW). Solasia filed an NDA with the MHLW in Japan in June 2021. In October 2021, Nippon Kayaku Co., Ltd. (TSE: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) secured a license agreement with DARVIAS^® for marketing rights in Japan.

DARVIAS^®, an organoarsenic compound with anticancer activity, is a novel mitochondrial-targeted agent being developed for the treatment of various hematologic and solid tumors. The proposed mechanism of action of the drug involves the disruption of mitochondrial function, increased production of reactive oxygen species, and modulation of intracellular signal transduction pathways. DARVIAS^® is believed to exert an anticancer effect by inducing cell cycle arrest and apoptosis. This approval is based on the result of an Asian Multinational phase II study of SP-02 in patients with relapsed or refractory PTCL, Japan being the first country in the world where it was approved.

Mr. Yoshihiro Arai, President and CEO of Solasia, commented for this approval as follows:

Since its founding, we have been focusing on developing new treatment options that solve the quality of life of patients in the treatment of cancer that affects one in two Japanese people. The two products, episil® Oral Solution and Sancuso®, which have been successfully developed so far, are not for the treatment of cancer itself, but used as supportive care such as suppression of nausea / vomiting caused by chemotherapy and alleviation of pain associated with oral mucositis caused by chemotherapy and radiotherapy. DARVIAS^® is our first NDA approved anticancer drug. Nippon Kayaku is our commercial partner with strengths in the field of oncology. We are very pleased to have this opportunity to deliver DARVIAS^® to nationwide medical institutions providing new cancer treatment by utilizing Nippon Kayaku’s extensive experience in oncology and contribute to the treatment of patients suffering from PTCL.

About DARVIAS^®

DARVIAS®, an organoarsenic drug, is a novel anticancer agent targeting mitochondria.

DARVIAS® provokes cell cycle arrest and apoptosis through disruption of mitochondrial functions and increased production of reactive oxygen species in tumor cells. In addition to the PTCL, it has been suggested that potential target indications be other hematologic cancers (lymphoma, leukemia), and solid tumors. Regarding future expansion of indications, Solasia will explore clinical development strategies in consultation with Nippon Kayaku. DARVIAS® has been granted orphan drug designation in the US and EU.

About Solasia

Solasia is a specialty pharmaceutical company based in Asia, with a mission to provide “Better Medicine for a Brighter Tomorrow.” To address the unmet medical needs in the oncology field, Solasia develops innovative medicines to contribute to the better health and brighter future of patients. Please visit the company website at https://solasia.co.jp/en/ for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005030/en/

Contacts

Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations,

Tel. +81 3 5843 8045

info@solasia.co.jp